v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 881 $ 7,141
Research and development tax credit receivable 404 519
Prepaid expenses and other current assets 1,079 849
Total current assets 2,364 8,509
Property, plant and equipment, net 221 269
Right-of-use assets, net 663 120
Other assets, non-current   6
Total assets 3,248 8,904
Current liabilities    
Accounts payable and accrued expenses 4,890 1,791
Lease liabilities, current 274 47
Other current liabilities 660 450
Total current liabilities 5,824 2,288
Lease liabilities, non-current 376 25
Total liabilities 6,200 2,313
Contingencies (Note 7)
Stockholders' (deficit) / equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 0 and 856 shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 5,605,043 and 3,590,217 shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively 1
Additional paid-in capital 123,495 122,316
Accumulated other comprehensive loss (3,374) (1,105)
Accumulated deficit (123,074) (114,620)
Total stockholders' (deficit) / equity (2,952) 6,591
Total liabilities and stockholders' (deficit) / equity $ 3,248 $ 8,904

Source

HTML PDF
ZIP